HBG2 -158 (C>T) polymorphism and its contribution to fetal hemoglobin variability in Iraqi Kurds with beta-thalassemia minor

ABSTRACT

PURPOSE: Hemoglobin (Hb) F% is increased in up to half of beta-thalassemia (β-thal) carriers. Several polymorphisms have been linked to such variability in different populations, including HBG2 - 158(C>T) (Xmn I polymorphism) on chromosome 11. To determine the role of this polymorphism in such variability among Iraqi Kurds, the current study was initiated.

MATERIALS AND METHODS: A total of 102 consecutive patients diagnosed as β-thal minor were enrolled. The enrollees had their diagnosis based on peripheral blood counts and high-performance liquid chromatography to determine HbA2 and HbF. All enrollees had their DNA extracted by phenol-chloroform method and Xmn I polymorphism detected by restriction fragment length polymorphism-polymerase chain reaction.

RESULTS: The mean age (standard deviation [SD]) of the 102 enrollees was 25.4 (14.0) years, and the enrollees included 48 males and 54 females. Xmn I polymorphism was identified in heterozygous state in 46 (45.1%) patients and in homozygous state in one patient (0.98%). Thus, the minor allele frequency of this polymorphism was 0.235 in the studied group. There were no significant differences in red cell indices and HbA2% in carriers of the minor allele compared to noncarriers, while HbF% and absolute HbF concentrations were significantly higher in the former subgroup (P = 0.032 and 0.014, respectively). This polymorphism's contribution to HbF variability was found to be 5.8% in the studied sample. Furthermore, those with HbF ≥2% were 3.2 folds more likely to carry the minor allele.

CONCLUSIONS: Xmn I polymorphism is frequently encountered in Iraqi Kurds with β-thal minor, and it is significantly associated with higher fetal hemoglobin in these patients.

Keywords

Beta-thalassemia - Iraq - Kurds - rs7482144 - Xmn I polymorphism

Publication History

Received: 12 February 2018

Accepted: 17 June 2018

Article published online:
20 February 2020

• REFERENCES

• 1 Kelly N. Thalassemia. Pediatr Rev 2012;33:434-5.
• 2 Ben Salah N, Bou-Fakhredin R, Mellouli F, Taher AT. Revisiting beta thalassemia intermedia: Past, present, and future prospects. Hematology 2017;22:607-16.
• 3 Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4^th ed. Oxford: Blackwell Scientific Publications; 2001.
• 4 Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia: Thalassemia International Federation; 2013. p. 3.
• 5 Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: New insights emerging from genomics and clinical implications. Hum Mol Genet 2009;18:R216-23.
• 6 Al-Allawi NA, Jalal SD, Mohammad AM, Omer SQ, Markous RS. β-thalassemia intermedia in Northern Iraq: A single center experience. Biomed Res Int 2014;2014:262853.
• 7 Al-Allawi NA, Puehringer H, Raheem RA, Oberkanins C. Genetic modifiers in β-thalassemia intermedia: A study on 102 Iraqi Arab patients. Genet Test Mol Biomarkers 2015;19:242-7.
• 8 Shamoon RP, Al-Allawi NA, Cappellini MD, Di Pierro E, Brancaleoni V, Granata F, et al. Molecular basis of β-thalassemia intermedia in Erbil province of Iraqi Kurdistan. Hemoglobin 2015;39:178-83.
• 9 Al-Allawi N, Nerwey F, Jassim D, Omer SQ, Jalal S, Markous RD. Xmn I polymorphism in thalassemia patients in Duhok. DMJ 2012;6:1-7.
• 10 Danjou F, Anni F, Perseu L, Satta S, Dessì C, Lai ME, et al. Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion. Haematologica 2012;97:989-93.
• 11 Banan M, Bayat H, Namdar-Aligoodarzi P, Azarkeivan A, Kamali K, Daneshmand P, et al. Utility of the multivariate approach in predicting β-thalassemia intermedia or β-thalassemia major types in Iranian patients. Hemoglobin 2013;37:413-22.
• 12 Pereira C, Relvas L, Bento C, Abade A, Ribeiro ML, Manco L,et al. Polymorphic variations influencing fetal hemoglobin levels: Association study in beta-thalassemia carriers and in normal individuals of Portuguese origin. Blood Cells Mol Dis 2015;54:315-20.
• 13 Vrettou C, Kanavakis E, Traeger-Synodinos J, Metaxotou-Mavrommati A, Basiakos I, Maragoudaki E, et al. Molecular studies of beta-thalassemia heterozygotes with raised Hb F levels. Hemoglobin 2000;24:203-20.
• 14 Traeger-Synodinos J, Kanavakis E, Vrettou C, Maragoudaki E, Michael T, Metaxotou-Mavromati A, et al. The triplicated alpha-globin gene locus in beta-thalassaemia heterozygotes: Clinical, haematological, biosynthetic and molecular studies. Br J Haematol 1996;95:467-71.
• 15 Guida V, Cappabianca MP, Colosimo A, Rafanelli F, Amato A, Dallapiccola B, et al. Influence of Ggamma-158C –> and beta- (AT)x(T) y globin gene polymorphisms on HbF levels in Italian beta-thalassemia carriers and wild-type subjects. Haematologica 2006;91:1275-6.
• 16 Old J, Traeger-Synodinos J, Galanello R, Petrou M, Angastiniotis M. Prevention of Thalassemia and other Hemoglobin Disorders. Vol. 2. Nicosia: Thalassemia International Federation; 2005.
• 17 Galanello R, Eleftheriou A, Traeger-Synodinos J, Old J, Petrou M, Angastiniotis M. Prevention of Thalassaemia and other Haemoglobin Disorders. Vol. 1. Nicosia: Thalassemia International Federation; 2003.
• 18 Garner C, Tatu T, Reittie JE, Littlewood T, Darley J, Cervino S, et al. Genetic influences on F cells and other hematologic variables: A twin heritability study. Blood 2000;95:342-6.
• 19 Gilman JG, Huisman TH. DNA sequence variation associated with elevated fetal G gamma globin production. Blood 1985;66:783-7.
• 20 Sampietro M, Thein SL, Contreras M, Pazmany L. Variation of HbF and F-cell number with the G-gamma xmn I (C-T) polymorphism in normal individuals. Blood 1992;79:832-3.
• 21 Mastropietro F, Modiano G, Cappabianca M, Foglietta E, D'Asero C, Mezzabotta M, et al. Factors regulating Hb F synthesis in thalassemic diseases. BMC Blood Disord 2002;2:2.
• 22 Available from: http://www.grch37.ensembl.org/Homo_sapiens/Variation/Population?r=11:5275669-5276669;v=rs7482144;vdb=variation; vf=4471836. [Last accessed on 2018 Jun 13].
• 23 Chinelato IS, Carrocini GC, Bonini-Domingos CR. XmnI polymorphism frequency in heterozygote beta thalassemia subjects and its relation to fetal hemoglobin levels. Rev Bras Hematol Hemoter 2011;33:483.
• 24 Ali N, Ayyub M, Khan SA, Ahmed S, Abbas K, Malik HS, et al. Frequency of gγ-globin promoter -158 (C>T) xmnI polymorphism in patients with homozygous/compound heterozygous beta thalassaemia. Hematol Oncol Stem Cell Ther 2015;8:10-5.
• 25 Gibney GT, Panhuysen CI, So JC, Ma ES, Ha SY, Li CK, et al. Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong Kong. Am J Hematol 2008;83:458-64.
• 26 Bahadir A, Atalay EO. Frequency of Gγ-globin promoter -158 (C>T) XmnI polymorphism in Denizli, Turkey. Int J Phys Sci 2012;7:1927-31.
• 27 Al-Allawi NA, Jubrael JM, Hughson M. Molecular characterization of beta-thalassemia in the Dohuk region of Iraq. Hemoglobin 2006;30:479-86.
• 28 Dedoussis GV, Mandilara GD, Boussiu M, Loutradis A. HbF production in beta thalassemia heterozygotes for IVS-II-1 G → A beta (0) –globin mutation. Implications of the haplotype and Gγ -158 C → T mutation on Hb F level. Am J Hematol 2000;64:151-5.
• 29 Chan NC, Lau KM, Cheng KC, Chan NP, Ng MH. A multi-locus approach to characterization of major quantitative trait loci influencing Hb F regulation in Chinese β-thalassemia carriers. Hemoglobin 2016;40:400-4.
• 30 Chen JF, Long GF, Lin WX, Chen P. Beta thalassemia mutations and single nucleotide polymorphism at -158 of the gamma-globin gene associated with altered levels of HbF in beta thalassemia heterozygotes. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2004;21:498-501.
• 31 Kanavakis E, Metaxotou-Mavromati A, Kattamis C, Wainscoat JS, Wood WG. The triplicated alpha gene locus and beta thalassaemia. Br J Haematol 1983;54:201-7.
• 32 Kutlar A, Kutlar F, Gu LG, Mayson SM, Huisman TH. Fetal hemoglobin in normal adults and beta-thalassemia heterozygotes. Hum Genet 1990;85:106-10.